Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
Conclusions In patients with P53WT advanced solid tumors or MM, AMG 232 showed acceptable safety and dose-proportional pharmacokinetics, and stable disease was observed.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Liposarcoma | Myeloma | Oral Cancer | Study | Thrombocytopenia | Toxicology